Forest Labs Expected to Reach Settlements and 4 Stock Analyses Not to Miss

Bed Bath & Beyond, Inc. (NASDAQ:BBBY) price target has been reduced by Deutsche Bank as a result of the company’s Q4 results. However, because the firm views the quarter as being no worse than expected and consensus estimates as being too high, it has decided to keep a Buy rating on the stock.

Forest Laboratories Inc. (NYSE:FRX) is predicted by Citigroup to be able to come to a settlement with the remaining generic challengers to Bystolic over the near-term. Citi is convinced that patent settlements to date favor Forest Labs, and the firm reiterates its Buy rating and increased the stock’s price target to $44.

Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.

MAKO Surgical Corp. (NASDAQ:MAKO): According to Piper Jaffray, its survey of existing MAKO Surgical sites has shown ongoing solid use and satisfaction regarding the Rio robotic arm surgical system. Piper claimed that it has greater conviction in MAKO after the survey, and it keeps its Overweight rating and a $28 price target on the stock.

General Motors Corporation (NYSE:GM) agreed to repurchase 200 million of its shares from the U.S. government, influencing RBC Capital to believe that the deal will raise the company’s 2013 EPS by nearly 13 percent. The firm continues to believe that the company’s balance sheet should continue to be very strong after the transaction, and it has decided to keep its Outperform rating on the stock.

Integrated Device Technology, Inc. (NASDAQ:IDTI): Canaccord has stated that the FTC’s intention to block Integrated Device’s proposed merger of PLX Technology (NASDAQ:PLXT) is a positive for the stock, and the firm thinks that it was unpopular with investors due to terms of price, cash, and execution risk. Shares have a Buy rating.

Don’t Miss: Consumers are Still Confident in Technology.